Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Open accessThe DOI matches its Crossref record; 78 of the 80 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. This condition is characterized by hyperandrogenism and either oligo- or anovulation. PCOS patients often present comorbidities such as obesity, insulin resistance, impaired glucose metabolism, dyslipidemia, hypertension, metabolic syndrome, and an increased risk of diabetes. Given the profound implications of metabolic impairment in PCOS, the accurate diagnosis and management of these facets are imperative. The first-line approach to treatment involves lifestyle modifications, including dietary adjustments and exercise aimed at achieving weight loss, a strategy consistently emphasized across the literature. Supplementation with probiotics, vitamin D, and L-carnitine have also provided additional benefits to patients. In select cases, pharmacological interventions are needed for optimal therapeutic results. The most common medications used in PCOS include metformin, thiazolidinediones, inositols, and two classes of antidiabetic agents: dipeptidyl peptidase-IV (DPP-IV) inhibitors, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new addition to the therapeutic arsenal for the metabolic management of PCOS. GLP-1 receptor agonists cause insulin release in a glucose-dependent manner, yielding clinical benefits such as heightened satiety, reduced appetite, and appetite regulation. GLP-1RAs have demonstrated efficacy in reducing glycated hemoglobin levels and promoting weight loss while ameliorating hyperlipidemia. Prior to initiating GLP-1RA therapy, patients should undergo screening for contraindications, including history of pancreatitis, diabetic retinopathy, or thyroid cancer. The effects of treatment should be monitored using laboratory testing and body weight measurements. Effective communication between clinician and patient should be maintained with regular check-in for a period of 6 to 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests that while GLP-1RAs may not outperform metformin in managing hormone levels, they are still beneficial in populations not already treated with metformin23–26.”
From Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials (2025) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Influence of diet on the gut microbiome and implications for human health
Singh, R. K., Chang, H.-W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T. H., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1175-y · Cited by 2,599 · cited 1×
“) adolescentis, a profile associated with an increased risk of cardiovascular disease [40].”
BackgroundPolycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · cited 1×
“Its prevalence is estimated to range from 6% to 20% [1] within this demographic.”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Insulin resistance (IR) is a hallmark of PCOS, with approximately 50–80% of PCOS patients affected [6].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919 · cited 1×
“In women with PCOS exhibiting menstrual irregularity where hormonal contraceptives are either contraindicated or not tolerated, metformin is advised as second-line therapy [47].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 1×
“In these cases, IR develops subsequently into a binding defect caused by excessive serine phosphorylation and diminished tyrosine phosphorylation [7].”
BackgroundObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · cited 1×
“…tailor treatment to a patient’s individual needs and involves steps such as raising patient awareness of obesity as a problem with metabolic consequences, seeking permission to implement treatment, setting realistic therapeutic goals, and assessing patient willingness to adhere to treatment [72].”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“However, subjective ratings of taste, visual appeal, smell, aftertaste, and overall palatability of test meals did not differ on two experimental days [31].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide across doses also reduced blood pressure and markedly reduced the prevalence of prediabetes (84–96% reduction) at doses of 1.8 to 3.0 mg per day [58].”
BackgroundInfluentialRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Multiple studies have addressed the effects of GLP-1 analogs on appetite, food preferences, and gastrointestinal hormones using varied doses, duration, and assessment methodologies [25,26].”
BackgroundLim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939 · cited 1×
“The incidence of obesity among PCOS patients is three-fold higher compared with women without PCOS [5].”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 3×
“While some weight rebound was observed in the liraglutide group after treatment cessation at week 160, the treatment-associated difference remained significant at week 172 (–3.2%, 95% CI − 4.3 to − 2.2, p 0.0001) [27].”
BackgroundInfluentialO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“It is via these pathways that they contribute to weight reduction by promoting satiety and delaying gastric emptying [30].”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“Notably, animal studies have suggested that GLP-1 may increase ß-cell mass through regeneration and a reduction in apoptosis [28,29].”
BackgroundSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · cited 1×
“Greater weight loss, particularly at higher doses of semaglutide and dulaglutide, has also been shown [55].”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“Caution is advised when administering GLP-1 analogs to patients concurrently on renin–angiotensin system inhibitors due to their heightened susceptibility to acute kidney injury resulting from dehydration and volume contraction [71].”
BackgroundBARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391 · cited 1×
“DPP-4 inhibitors increase the active levels of incretin hormones in the body, regulating elevated blood glucose by stimulating pancreatic insulin secretion, suppressing pancreatic glucagon secretion, and signaling the liver to reduce glucose production [52].”
BackgroundObesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356 · cited 4×
“Subcutaneous liraglutide 3 mg once daily is indicated as an adjunct to chronic body weight management in adults with a BMI ≥ 30 kg/m 2 or BMI of ≥ 27 kg/m 2 and at least one weight-related comorbidity, including hypertension, dyslipidemia, obstructive sleep apnea, or type 2 diabetes [18].”
BackgroundInfluentialEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352 · cited 3×
“GLP-1 analogs promote weight loss via numerous mechanistic routes [23], including: The intricate interplay between brain and gut hormones orchestrates the roles of both physiological and pharmacological GLP-1 in modulating appetite [24].”
BackgroundDapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350 · cited 1×
“These inhibitors target glucose reabsorption from the proximal tubules of the kidneys [53].”
BackgroundArd, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297 · cited 3×
“When combined with basal insulin, GLP-1 receptor agonists exhibit potent glucose-lowering effects while minimizing weight gain and hypoglycemia when compared with intensified insulin regimens [16].”
BackgroundInfluentialHe, F.-F., & Li, Y.-M. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00670-3 · Cited by 289 · cited 1×
“Furthermore, disturbances in normal intestinal flora have also been shown to play a role in the pathomechanism of IR [9].”
BackgroundInsulin and the polycystic ovary syndrome
Macut, D., Bjekić-Macut, J., Rahelić, D., & Doknić, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.011 · Cited by 261 · cited 1×
“Additionally, they improve menstrual cycle irregularity, promote ovulation, and reduce androgen levels in women with PCOS [49,50].”
BackgroundVitamin D: emerging new roles in insulin sensitivity
Teegarden, D., & Donkin, S. S. (2009) · Nutrition Research Reviews · doi:10.1017/s0954422409389301 · Cited by 260 · cited 1×
“Vitamin D contributes to insulin synthesis, enhances insulin receptor expression, and amplifies insulin response to glucose transport [42].”
BackgroundPolycystic ovary syndrome and mitochondrial dysfunction
Zhang, J., Bao, Y., Zhou, X., & Zheng, L. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0509-4 · Cited by 258 · cited 1×
“Moreover, mitochondrial dysfunction is also considered a potential contributor to the increased prevalence of NAFLD in PCOS [13].”
BackgroundGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · cited 3×
“In a three-year trial focused on obesity and prediabetes, it was found that liraglutide at a dosage of 3mg exhibited potential health benefits by reducing diabetes risk among patients with obesity and prediabetes [22].”
BackgroundInfluentialDiamanti-Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. N. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 247 · cited 1×
“Metformin, which lowers serum glucose levels by inhibiting hepatic glucose production [46], is recommended as a first-line medication for women with PCOS and T2DM or impaired glucose tolerance and have not responded to lifestyle modification.”
BackgroundBunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · cited 1×
“[32].”
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236 · cited 2×
“Consequently, the potential for gastrointestinal side effects can potentially be amplified in this group of patients [33].”
BackgroundMetabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228 · cited 2×
“Following a ketogenic diet has also been suggested to alleviate symptoms such as irregular menses and impaired liver function associated with PCOS [10].”
BackgroundWang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225 · cited 1×
“In diabetic patients, the use of GLP-1RAs has been associated with significant reductions in glycated hemoglobin, weight loss, modest lowering of blood pressure, and improved hyperlipidemia [56,57].”
BackgroundSalamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204 · cited 3×
“In a study on rats, treatment with GLP-1 during the proestrus phase doubled the LH serum level and resulted in exerting progesterone in the luteal phase, which constantly increased the number of mature Graafian follicles, resulting in increased fertility [66].”
BackgroundInfluentialElkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J., & Bellanger, D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.04.027 · Cited by 182 · cited 1×
“The authors found that liraglutide at a dose of 3 mg once daily was superior to placebo for weight loss, reducing hyperandrogenism, and improving cardiometabolic parameters among women with PCOS and obesity [62].”
BackgroundEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · cited 1×
“8 mg/day or placebo for 26 weeks showed that treatment with liraglutide reduced body weight significantly by over 5%, liver fat by 44%, visceral adipose tissue by 18%, and free testosterone level by 19% [60].”
BackgroundMeyer, M. L., Malek, A. M., Wild, R. A., Korytkowski, M. T., & Talbott, E. O. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr046 · Cited by 175 · cited 1×
“Markers of these dysfunctions often correlate with flow-mediated dilatation, carotid intima-media thickness, and the presence of coronary artery disease [12].”
BackgroundKadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166 · cited 2×
“In a 2020 study, thirty-five participants in a liraglutide group demonstrated significant reductions in prospective food consumption scores and in the desire for sweet, salty, savory, or fatty foods, as well as heightened perception of fullness [26].”
BackgroundNutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review
Szczuko, M., Kikut, J., Szczuko, U., Szydłowska, I., Nawrocka-Rutkowska, J., Ziętek, M., Verbanac, D., & Saso, L. (2021) · Nutrients · doi:10.3390/nu13072452 · Cited by 165 · cited 1×
“Such diets have shown decreased homeostatic model assessment for insulin resistance (HOMA-IR), fasting insulin levels, total and low-density lipoprotein (LDL) cholesterol, triglycerides, waist circumference, and total testosterone [38].”
BackgroundMicrobiome and PCOS: State-of-Art and Future Aspects
Giampaolino, P., Foreste, V., Di Filippo, C., Gallo, A., Mercorio, A., Serafino, P., Improda, F. P., Verrazzo, P., Zara, G., Buonfantino, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042048 · Cited by 163 · cited 1×
“Dietary interventions hold therapeutic promise for various chronic diseases, particularly those linked to metabolic syndrome, by modulating the microbiome [37].”
BackgroundJamilian, M., Mansury, S., Bahmani, F., Heidar, Z., Amirani, E., & Asemi, Z. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0457-1 · Cited by 156 · cited 1×
“…reuteri , Lactobacillus fermentum , and Bifidobacterium bifidum ) and a daily 200 µ g dose of selenium for 12 weeks yields favorable outcomes in mental health parameters, serum total testosterone, hirsutism, hs-CRP, total antioxidant capacity, and malondialdehyde levels in women with PCOS [41].”
BackgroundPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156 · cited 3×
“Simultaneous administration of MI and DCI in a 40:1 ratio has shown efficacy in restoring ovulation [51].”
BackgroundNylander, M., Frøssing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.03.023 · Cited by 139 · cited 1×
“This suggests that the influence of treatment on this particular assessment parameter might require a longer duration to achieve a substantive change [74].”
BackgroundSafety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130 · cited 1×
“An analysis of potential safety and tolerability issues associated with GLP-1 analogs found the risk of hypoglycemia, injection-site reactions, pancreatitis, neoplasms, and gallbladder events to be generally low [20].”
BackgroundWehr, E., Pieber, T. R., & Obermayer-Pietsch, B. M. (2011) · PubMed · doi:10.3275/7748 · Cited by 126 · cited 1×
“Studies have indicated that women with PCOS receiving a weekly dose of 20,000 IU of cholecalciferol experienced enhanced carbohydrate metabolism, including a reduction in fasting glucose, triglycerides, and estradiol levels [43].”
BackgroundAldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387116 · Cited by 115 · cited 3×
“GLP-1 analogs promote weight loss via numerous mechanistic routes [23], including:”
BackgroundZhao, H., Xing, C., Zhang, J., & He, B. (2021) · Reproductive Health · doi:10.1186/s12978-021-01207-7 · Cited by 113 · cited 2×
“However, their utilization is constrained due to their numerous side effects such as weight gain, peripheral edema, and heart failure [48].”
BackgroundNewer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110 · cited 4×
“Furthermore, it significantly inhibits gastric emptying, preventing swift glucose entry into systemic circulation—a pivotal factor in postprandial glucose fluctuations [28].”
BackgroundInfluentialYilmaz, M., Bi˙ri˙, A., Bukan, N., Karakoç, A., Sancak, B., Törüner, F., & Paşaoğlu, H. (2005) · Gynecological Endocrinology · doi:10.1080/09513590400027265 · Cited by 106 · cited 1×
“Notably, PCOS patients exhibit distinctive atherogenic lipid profiles, characterized by elevated serum levels of LDL-cholesterol, decreased levels of HDL-cholesterol, and an increase in serum triglyceride levels [11].”
BackgroundJensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103 · cited 1×
“Liraglutide treatment also significantly reduced visceral adipose tissue area [59].”
BackgroundLife Modifications and PCOS: Old Story But New Tales
Gu, Y., Zhou, G., Zhou, F., Wu, Q., Ma, C., Zhang, Y., Ding, J., & Hua, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.808898 · Cited by 103 · cited 1×
“To maximize efficacy, a weekly regimen should include a minimum of 90 min of intensive exercise [36].”
BackgroundEffects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97 · cited 2×
“It is noteworthy that these symptoms are generally most intense during the early stages of treatment and tend to alleviate over time [77].”
BackgroundThe risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta‐analysis
Behboudi‐Gandevani, S., Amiri, M., Bidhendi Yarandi, R., Noroozzadeh, M., Farahmand, M., Rostami Dovom, M., & Ramezani Tehrani, F. (2018) · Clinical Endocrinology · doi:10.1111/cen.13477 · Cited by 88 · cited 2×
“Obesity is one of the most important metabolic issues afflicting PCOS patients, with estimates suggesting that at least 50% of individuals with PCOS are obese [4].”
BackgroundUpdate on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82 · cited 1×
“Siamashvili et al. compared exenatide with metformin and demonstrated a signifi-cantly greater number of spontaneous pregnancies in the exenatide group after 24 weeks of treatment [67].”
BackgroundKahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12369 · Cited by 79 · cited 1×
“This observation introduces an additional factor when considering the use of liraglutide in women with PCOS, obesity, and non-alcoholic fatty liver disease [63].”
BackgroundExercise and Polycystic Ovary Syndrome
Woodward, A., Klonizakis, M., & Broom, D. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_8 · Cited by 77 · cited 1×
“PCOS guidelines advocate for a minimum of 150 min of physical activity per week [35].”
BackgroundKahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74 · cited 1×
“%) and had decreased atherothrombosis markers such as inflammation, endothelial function, and clotting [61].”
BackgroundA systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66 · cited 1×
“During the same period, 88 women exhibited a decrease of 0.29 nmol/L in serum testosterone levels [73].”
BackgroundInfluentialLie Fong, S., Douma, A., & Verhaeghe, J. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101894 · Cited by 64 · cited 2×
“Dropouts are common, as shown in a lifestyle intervention study by Fong et al., who observed discontinuation rates varying between 12% and 47% in overweight and obese women with PCOS [39].”
BackgroundPanunzi, S., Maltese, S., Verrastro, O., Labbate, L., De Gaetano, A., Pompili, M., Capristo, E., Bornstein, S. R., & Mingrone, G. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14304 · Cited by 61 · cited 1×
“Additionally, they improve menstrual cycle irregularity, promote ovulation, and reduce androgen levels in women with PCOS [49,50].”
BackgroundAbdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821989238 · Cited by 60 · cited 1×
“A review by Abdalla et al. showed that in clinical trials, exenatide, either in combination with metformin or in monotherapy, improves menstrual regularity and ovulation rate in overweight or obese women with PCOS, which directly translates to enhanced fertility [68].”
BackgroundTan, S., Ignatenko, S., Wagner, F., Dokras, A., Seufert, J., Zwanziger, D., Dunschen, K., Zakaria, M., Huseinovic, N., Basson, C. T., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14495 · Cited by 57 · cited 1×
“Furthermore, 50mg of licogliflozin administered three times daily effectively reduced hyperinsulinemia and hyperandrogenemia in women with PCOS, hinting at its potential as a promising novel treatment [54].”
BackgroundJensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50 · cited 1×
“Therefore, women in their reproductive years should be on effective contraception while on therapy and have a washout period before trying to conceive [69].”
BackgroundPotential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 50 · cited 1×
“A trial including 150 women with PCOS with impaired fasting glucose and/or impaired glucose tolerance demonstrated a prediabetes remission rate of 64% with combined treatment, 56% with exenatide only, and 32% with metformin only [65].”
BackgroundCardiometabolic biomarkers in women with polycystic ovary syndrome
van der Ham, K., Louwers, Y. V., & Laven, J. S. E. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.008 · Cited by 49 · cited 1×
“This spectrum of issues is pertinent to a wide range of PCOS patients, including adolescents, women in their reproductive years, pregnant women, and postmenopausal women [3].”
Backgroundvan Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46 · cited 1×
“In diabetic patients, the use of GLP-1RAs has been associated with significant reductions in glycated hemoglobin, weight loss, modest lowering of blood pressure, and improved hyperlipidemia [56,57].”
BackgroundKahal, H., Kilpatrick, E., Rigby, A., Coady, A., & Atkin, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1505848 · Cited by 45 · cited 1×
“Furthermore, a significant improvement was observed in social health, physical well-being, and psychological components of the World Health Organization QOL questionnaire (WHOQOL-BREF) [64].”
BackgroundDong, L., Hou, X., Liu, F., Tao, H., Zhang, Y., Zhao, H., & Song, G. (2019) · Cell Biology International · doi:10.1002/cbin.11129 · Cited by 42 · cited 1×
“Alternative mechanisms are linked to microRNA alterations that are observed in PCOS patients and suspected mitochondrial dysfunction linked to oxidative stress contributing to IR [8].”
BackgroundCoveleskie, K., Kilpatrick, L. A., Gupta, A., Stains, J., Connolly, L., Labus, J. S., Sanmiguel, C., & Mayer, E. A. (2017) · Obesity Science & Practice · doi:10.1002/osp4.124 · Cited by 40 · cited 1×
“Coveleski et al. conducted a study showcasing that the administration of GLP-1 analogs reduced the sensation of hunger in obese women through direct enhancement in functional connectivity between the left nucleus tractus solitarius and the left thalamus and hypothalamus [15].”
BackgroundOtaghi, M., Azami, M., Khorshidi, A., Borji, M., & Tardeh, Z. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.002 · Cited by 38
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 38 · cited 1×
“While initial GLP-1 agonists were available solely in injectable formulations, recent developments have introduced oral formulations, such as oral semaglutide [17].”
BackgroundDiagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?
Andersen, M., & Glintborg, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0237 · Cited by 36
Metabolic health during a randomized controlled lifestyle intervention in women with PCOS
Dietz de Loos, A., Jiskoot, G., Beerthuizen, A., Busschbach, J., & Laven, J. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0669 · Cited by 33 · cited 1×
“The current first-line approach to treat-ment involves lifestyle interventions including diet, exercise, and behavioral therapy [34].”
BackgroundSangouni, A. A., Pakravanfar, F., Ghadiri‐Anari, A., Nadjarzadeh, A., Fallahzadeh, H., & Hosseinzadeh, M. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02659-0 · Cited by 33 · cited 1×
“However, a 12-week trial demonstrated that L-carnitine exhibited no discernable effect on SHBG and lipid profile [45].”
BackgroundTauqir, S., Israr, M., Rauf, B., Malik, M. O., Habib, S. H., Shah, F. A., Usman, M., Raza, M. A., Shah, I., Badshah, H., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01789-5 · Cited by 29 · cited 1×
“Significant improvements in testosterone, FSH, and LH levels were also reported [44].”
BackgroundGill, L. A., & Mackey, S. (2021) · Journal of Women s Health · doi:10.1089/jwh.2020.8683 · Cited by 23 · cited 3×
“GLP-1RAs do not increase the risk of hypoglycemia but exhibit a good safety profile and are generally well tolerated in PCOS management [70].”
BackgroundInfluentialRole of obstructive sleep apnea in metabolic risk in PCOS
Sam, S., & Tasali, E. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.01.002 · Cited by 21 · cited 1×
“Sleep apnea is yet another condition associated with PCOS and of which PCOS patients have an increased risk of developing [14].”
Background
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“49 A meta-analysis in women with polycystic ovary syndrome and overweight or obesity found that GLP-1 RA use was associated with improvements in menstrual regularity (standardized mean difference: 1.72, 95% CI 0.60, 2.85) compared to metformin or placebo, and spontaneous pregnancy rate (RR: 1.72,…”
InfluentialThe last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment
Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100228 · Cited by 92
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., et al. (2024) · Medicina · doi:10.3390/medicina60101656 · Cited by 63
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently become a valuable option for the metabolic management of polycystic ovarian syndrome (PCOS) [124].”
BackgroundLin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-99622-4 · Cited by 35
“This suggests that while GLP-1RAs may not outperform metformin in managing hormone levels, they are still beneficial in populations not already treated with metformin 23–26 .”
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
Metadata
- Authors
- Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B.
- Affiliations
- Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- Poznan University of Medical Sciences (PL)
- University College Dublin (IE)
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-09-12
- Volume
- 12
- Issue
- 18
- Pages
- 5915
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10532286
- OpenAlex
- W4386686806
- Cited by
- 83
- References
- 80
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 15
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- polycystic ovary syndrome, GLP-1 receptor agonists, insulin resistance, weight loss, hyperandrogenism, metabolic comorbidities, lifestyle modification, metformin, DPP-4 inhibitors, SGLT2 inhibitors, myo-inositol, thiazolidinediones, probiotics, vitamin D, L-carnitine, HbA1c, hyperlipidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.